LXRX vs SAP
Lexicon Pharmaceuticals Inc (LXRX) versus SAP (SAP) — a side-by-side from cached financials, not a winner call.
Lexicon Pharmaceuticals Inc (LXRX) is a biotechnology company listed on US.
SAP (SAP) common stock.
Latest reported LXRX revenue for 2026-06-30 was $21.8M. Net income was -$32.8M. Revenue was up 3.3% from 2026-03-31 to 2026-06-30. LXRX currently screens at market cap $327.2M.
SAP does not have a complete income-statement cache yet.
LXRX currently screens at market cap $327.2M. SAP currently screens at market cap $0.
Not investment advice. Open the LXRX and SAP stock pages for the full models.
Not investment advice.